In a February 4, 2022 news release Valneva/Pfizer reported positive Phase 2 data findings for their Lyme disease vaccine candidate, VLA15. According to the news release, findings of the Phase […]
Search Results for: vaccine
Giving Tuesday: Help LDA Help You/Persistence of Lyme Bacteria/Lyme Bacteria in Bats/Lyme: mRNA Vaccine/Shrews Harbor Powassan Virus/Another Lyme Bacteria in Ticks/LymeAid 4 Kids
Two Literati with Lyme authors had this to say about supporting the Lyme Disease Association’s Giving Tuesday campaign: Amy Tan- Internationally acclaimed author who helped initiate LDA’s LymeAid 4 Kids: “It’s Giving Tuesday! Many thanks to those who give generously to enable kids to get properly diagnosed and treated. You are making a profound difference in the lives of kids and their families.”
Sajid, et al., published in the journal Science Translational Medicine about the development of a promising mRNA vaccine, 19ISP, which has been found to induce tick resistance and prevent transmission of the Lyme disease-causing agent, Borrelia burgdorferi (Bb).
Ticks & Biowarfare Investigation Passes House/Last Chance to Register for LDA Conf. Before Price Increase/COVID Impacts on Lyme Reporting/Monoclonal Antibody COVID Treatment/LDA Doctor Referral Now Open/Valneva Lyme Vaccine
The Lyme Disease Association announces that the House voted this week to pass a number of amendments to the NDAA, National Defense Authorization Act, including a Congressman Chris Smith amendment.
Findings of a recent study, Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence, show that Moderna’s COVID-19 vaccine appears to have a […]
Increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna) since April 2021, particularly in adolescents and young adults. These rates for ages 16-24 following a second dose are above what is expected. Myocarditis or pericarditis has now been verified in 226 people ages 30 and younger who have received an mRNA COVID-19 vaccine and Federal Health Officials are investigating reports of approximately 250 more cases.
Due to this increase, the Advisory Committee on Immunization Practices (ACIP) is scheduled to hold an emergency meeting on June 18, 2021 to discuss myocarditis cases and the American Academy of Pediatrics (AAP) plans to closely monitor meeting.
Assessing the Safety Profile of mRNA-Based Vaccines in Patients with Autoimmune Inflammatory Rheumatic Diseases
A case series assessing the safety profile of mRNA-based vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) has been published in the journal Rheumatology. The study’s authors aim to raise awareness of reactivation of herpes zoster (HZ) following the BNT162b2 mRNA vaccination in patients with AIIRD.
Pfizer has received priority review for their vaccine, TicoVac, that protects against tick-borne encephalitis. This tick-borne virus can cause meningitis and trigger long-term neurological symptoms. If approved, the vaccine would potentially protect travelers as well as members of the US military that are deployed to regions where the virus is common, such as Europe and parts of Asia.
Valneva and Pfizer announced that they have initiated a Phase 2 study for their Lyme disease vaccine candidate. This new study builds on previous studies, including new dose regimens as well as being the first clinical study to include children between the ages 5-17 years.